Stay updated on Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.

Latest updates to the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page
- Check4 days agoChange DetectedThe page footer now includes Moffitt branding and related trial links. The revision label changed from v3.5.4 to v3.5.5.SummaryDifference0.3%

- Check11 days agoChange DetectedThe page’s footer now omits the H. Lee Moffitt Cancer Center branding and the sponsor-provided links to drug information, study documents, and helpful resources. This changes how the page references its affiliated institution and directs users to related materials.SummaryDifference0.3%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRevision label updated from v3.5.3 to v3.5.4, indicating a minor site/template update.SummaryDifference0.1%

- Check47 days agoChange DetectedThe page revision label was updated from **v3.5.2** to **v3.5.3**, indicating a newer site/application version for the same study record.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.